Lupin signs license and supply agreement with Zentiva

09 Jul 2025 Evaluate

Lupin has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of the company’s biosimilar Certolizumab Pegol. The company will be responsible for the development, manufacturing and supply of the product within the agreed territories, whereas, Zentiva will oversee commercialization activities in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. 

The company will undertake commercialization in the remaining regions, including USA and Canada.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2340.75 39.05 (1.70%)
10-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1813.00
Dr. Reddys Lab 1313.90
Cipla 1333.10
Zydus Lifesciences 922.90
Lupin 2340.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×